[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fundació Institut Germans Trias i Pujol\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":185},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,51,79,106,134,158],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100637977","acute-effects-of-jgermeister-with-energy-drinks-jgermbomb-100637977",false,"NCT07588022","Acute Effects of Jägermeister With Energy Drinks (Jägermbomb)","Acute Effects of an Explosive Cocktail With Energy Drinks That is Trendy Among Young People, the Jägerbomb","JB","Inclusion Criteria:\n\n1. Men and women between 18-45 years old with a weight between 50-90 kg for men and between 55-80 kg for women, and a body mass index (BMI) between 19-28 kg\u002Fm2. Lower or higher weights or BMIs are allowed, in the opinion of the Principal Investigator or the collaborators designated by the Principal Investigator and that do not pose a risk to the subjects and do not interfere with the objectives of the study.\n2. Alcohol consumption in the form of occasional binge drinking (≥1 time\u002Fmonth), social alcohol consumption (≥10g\u002Fday distributed weekly) and experience in alcohol intoxication.\n3. Consumption ≥7 drinks with methylxanthines (coffee, tea, chocolate, cola, BE) per week and who have consumed ED on at least one occasion.\n4. Understand and agree to the trial procedures and sign an informed consent.\n5. History and physical examination that demonstrate no organic or psychiatric disorders.\n6. The ECG and general blood and urine tests performed before the test should be within normal limits. Minor or punctual variations from the limits of normality are allowed if, at the discretion of the Principal Investigator, taking into account the state of science, they are not of clinical significance, do not pose a risk to the subjects and do not interfere with the assessment of the product. These variations and their non-relevance will be justified in writing in a specific way.\n\nExclusion Criteria:\n\n1. Not meeting the inclusion criteria.\n2. History or clinical evidence of gastrointestinal, liver, renal or other disorders that may involve an alteration in the absorption, distribution, metabolism or excretion of the drug, or that are suggestive of gastrointestinal irritation by drugs.\n3. Current history of substance use disorder according to DSM-V (except nicotine). A previous history of mild substance use disorder (corresponding to substance abuse according to DSM-IV criteria) is admitted.\n4. History or clinical evidence of psychiatric disorders, alcoholism, abuse of drugs or other drugs or habitual consumption of psychoactive drugs.\n5. Have participated in clinical trials with drugs or nutraceuticals in the previous 12 weeks.\n\n5\\) Have suffered any organic disease or major surgery in the three months prior to the start of the study.\n\n6\\) Subjects who have an intolerance or have had serious adverse reactions to alcohol. The inclusion of subjects of oriental origin who do not have an intolerance to alcohol will be allowed.\n\n7\\) Have taken medication regularly in the month prior to the study sessions, with the exception of vitamins, herbal remedies, or dietary supplements that, in the judgment of the Principal Investigator or collaborators designated by the Principal Investigator, do not pose a risk to the subjects and do not interfere with the objectives of the study. Treatment with single doses of symptomatic medication in the week prior to study sessions will not be grounds for exclusion if it is assumed to have been completely eliminated on the day of the experimental session.\n\n8\\) Smokers of \\>5 cigarettes a day. 9) Consumption of more than 20 g of alcohol daily in women and more than 40 g in men.\n\n10\\) Consumers of more than 5 coffees, teas, colas, or other stimulant or xanthine beverages daily in the 3 months prior to the start of the study.\n\n11\\) Subjects who are not able to understand the nature of the trial and the procedures they are asked to follow.\n\n12\\) Subjects with positive serology for hepatitis B, C or HIV. 13) Women who are pregnant or breastfeeding, or who use hormonal contraceptives or do not use reliable contraceptive measures during the study (such as abstinence, intrauterine devices, barrier methods or with a vasectomized partner).\n\n14\\) Women with amenorrhea or premenstrual syndrome of severe intensity.",true,"ALL","18 Years","45 Years",{"count":22,"type":23},24,"ESTIMATED","INTERVENTIONAL",[26],"NA","The main objective of this study is to compare the acute effects of drinking Jägerbombs with drinking alcohol alone during a binge-drinking episode, which involves consuming a large amount of alcohol in a short period of time to become intoxicated. Secondary objectives are to assess whether Jägerbombs produce prototypical alcohol effects, increase stimulation and rewarding effects, affect coordination, time reaction and vision, change stress-related hormone responses, and cause hangover symptoms.",[29,30,31,32],"Alcohol Drinking","Healthy Adult Participants","Binge Alcohol Consumption","Energy Drinks",[34,35,36,37],"Binge drinking","Jägerbomb","Alcohol","Psychomotor performance","RECRUITING","2026-05-08",{"date":41,"type":42},"2026-05-14","ACTUAL",{"date":44,"type":42},"2026-02-18",{"date":46,"type":23},"2027-06",{"name":48,"class":49},"Fundació Institut Germans Trias i Pujol","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":59,"targetDuration":61,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100622578","the-spanish-national-registry-for-myotonic-dystrophy-type-1-100622578","NCT07385443","The Spanish National Registry for Myotonic Dystrophy Type 1","Creación de un Nodo Integral Para la Distrofia Miotónica Tipo 1 en España: Registro clínico, Mapas genómicos, epigenómicos y proteómicos (DM1-Hub)","DM1-Hub","Inclusion Criteria:\n\n* Confirmed diagnosis of Myotonic Dystrophy Type 1 (DM1) through genetic testing.\n\nExclusion Criteria:\n\n* There are no exclusion criteria for the registry",{"count":60,"type":23},3000,"10 Years","OBSERVATIONAL","Myotonic Dystrophy Type 1 (DM1) is a rare genetic neuromuscular condition that can affect multiple organs and varies widely in how it presents. DM1 is the most common form of adult-onset muscular dystrophy, with an estimated prevalence of approximately 1-5 per 10,000 people. In Spain, the condition shows notable regional differences, making it especially important to understand its characteristics within the population.\n\nThe aim of this study is to support a research initiative designed to better characterise DM1. We are developing a comprehensive national registry, collecting patient-reported information, clinical data and omics data that will improve our understanding of the disease and help identify individuals who may be eligible for clinical trials.",[65,66,67,68,69],"Myotonic Dystrophy 1","DM1","Myotonic Dystrophy Type 1","Myotonic Dystrophy, Congenital","Steinert Disease","2026-01-29",{"date":72,"type":42},"2026-02-04",{"date":74,"type":42},"2025-06-02",{"date":76,"type":23},"2026-12-31",{"name":48,"class":49},8,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":87,"minAge":19,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":24,"phases":90,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":50},"100603894","effectiveness-of-a-multicomponent-behavioural-intervention-to-reduce-endocrine-disruptor-exposure-during-perinatal-period-continue-100603894","NCT07142447","Effectiveness of a multicOmpoNent Behavioural intervenTion to Reduce endocrINe disrUptor Exposure During pErinatal Period (CONTINUE)","Understanding and Preventing the Impact of Endocrine Disruptors on the Hypothalamus-pituitary Axis in Sensitive Populations. Hypiend- Perinatal Study.","CONTINUE","Inclusion Criteria:\n\n* Pregnant women with a viable pregnancy confirmed by ultrasound until 13 weeks and 0 days of gestation (recruitment between 6-11 weeks). Their partners will be invited to participate but this is not mandatory for inclusion.\n* BMI at Visit 1 between 18.5-40 kg\u002Fm²\n* Intention to breastfeed\n* Being able to read the language of their respective countries (Dutch\u002FFrench -Belgium-, Spanish and\u002For Catalan -Spain- and Polish -Poland)\n* Being 18 years or older\n* In possession of a smartphone. If participants do not have a smartphone because of socio-economic reasons, a smartphone will be at their disposal for the whole duration of the study\n\nExclusion Criteria:\n\n* Unable to sign informed consent (cultural barriers, psychological conditions)\n* Abuse of substances (alcohol, drugs)\n* Chronic use (at least, for three months before pregnancy) of any medication that might affect the HP axis:\n* Antidepressants\n* Insuline.\n* Levothyroxine, Methimazole, Propylthiouracil.\n* Oral corticosteroids (topical and inhalation formulations will be allowed)\n* Arginine vasopressin (AVP)\n* Mifepristone.\n* Anticortisolic drugs: Metyrapone (Metopirone), Ketokonazole, Osilodrostat (Isturisa), Mitotane (Lysodren), aminoglutethimide (Cytadren) and Levoketoconazole (Recorlev).\n* Multiple gestation\n* Type 1 or 2 diabetes\n* Pregnant women will not be consented into research by any HCP with whom they have a dependent relationship (Declaration of Helsinki) (I would remove this point).","FEMALE",{"count":89,"type":23},810,[26],"The general objective of HYPIEND is to understand the effects of chemical substances called \"endocrine disruptors\" (EDCs) during the perinatal and pre-pubertal stages. EDCs co-exposure may affect the function of hormones and determine endocrine consequences in vulnerable populations.\n\nThe primary objective of this clinical study is to demonstrate that a multicomponent intervention implemented in health care centres from three European countries is effective in reducing the levels of EDCs in different body fluids of pregnant women, breastfeeding and formula feeding women as well as in their infants up to 18 months of age, improving at the same time the level of HAPA constructs (psychological determinants of behaviour) and the knowledge about these chemicals at family level.",[93,94],"Pregnancy","Children",[96,97],"Endocrine Disruptors","hormones","2025-08-22",{"date":100,"type":42},"2025-08-26",{"date":102,"type":42},"2025-02-24",{"date":104,"type":23},"2027-07",{"name":48,"class":49},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":17,"sex":114,"minAge":19,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":117,"conditions":118,"keywords":122,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":4},"100599532","pan-viral-screening-and-linkage-to-care-among-gbmsm-and-trans-women-in-spain-100599532","NCT07085715","Pan-Viral Screening and Linkage to Care Among GBMSM and Trans Women in Spain","Optimizing Pan-Viral Screening and Linkage to Treatment and Vaccination Among GBMSM and Trans Women in Spain, Including PrEP Users and Those Awaiting Access: An Online Self-Sampling Pilot Study","PAN-TESTATE","Inclusion Criteria:\n\n* Men self-reporting being gay, bisexual, and other men who have sex with men (GBMSM) or transgender women\n* 18 years old or older\n* Residing in Spain\n* Accepting to participate and signing the informed consent\n* Including those who are in PrEP or waiting access to PrEP; regardless of their HIV status (HIV-negative or HIV-positive), and considered at risk for HCV acute infection using the MOSAIC validated algorithm (score of 2 or higher).\n\nExclusion Criteria:\n\n* \\\u003C18 years old\n* No GBMSM or transgender women\n* Non-residents in Spain\n* No signing the informed consent\n* Not considered at risk for HCV acute infection using the MOSAIC validated algorithm (score lower than 2).","MALE",{"count":116,"type":23},500,"The World Health Organization (WHO) aims to eliminate viral hepatitis as a public health threat by 2030, with major reductions in hepatitis B and C incidence and mortality. However, hepatitis C virus (HCV) transmission has increased among gay, bisexual, and other men who have sex with men (GBMSM), especially those living with HIV. Practices such as chemsex, particularly involving injection drug use, have contributed to this rise. Hepatitis B virus (HBV) also remains a public health challenge due to the potential for chronic infection and severe liver damage. Hepatitis D virus (HDV), which requires HBV co-infection, further complicates clinical management.\n\nThis study aims to design, implement, and evaluate an online self-sampling testing strategy to enhance pan-viral testing (HBV, HCV, HDV, HIV) and improve linkage to care among GBMSM and transgender women (TW) in Spain.\n\nThe intervention will involve self-collected dried blood spot (DBS) samples for testing HBV surface antigen (HBsAg), HIV antibodies, and HCV RNA. Individuals testing positive for HBsAg will undergo further testing for HBV DNA and HDV infection. Those lacking protective levels of HBV antibodies will be referred for vaccination or revaccination.\n\nThe study will also assess the number of HIV-positive individuals who acquired the infection while waiting for access to PrEP, identifying missed prevention opportunities.\n\nThis non-randomized, single-arm, prospective national study will recruit adult GBMSM and TW through PrEP services, dating apps, NGOs, social media, and community outreach. Participants will complete an online risk assessment (using the HCV-MOSAIC algorithm) and receive self-sampling kits with instructions, lancets, Whatman cards, and prepaid envelopes. Results will be provided online, and those testing positive will be linked to confirmatory diagnosis and care.\n\nOutcomes include estimates of HIV, HBV, HCV, and HDV prevalence; effectiveness of linkage to care; acceptability and usability of the intervention; and validation of DBS for HBsAg detection.\n\nThis study will provide critical evidence on the effectiveness of online self-sampling strategies for viral hepatitis and HIV among GBMSM and TW, supporting Spain's public health goals for prevention, early diagnosis, and linkage to care.",[119,120,121],"HIV","Hepatitis B","Hepatitis C",[123,124],"Self-sampling","Screening","NOT_YET_RECRUITING","2025-07-24",{"date":128,"type":42},"2025-07-25",{"date":130,"type":23},"2025-10",{"date":132,"type":23},"2026-12",{"name":48,"class":49},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":142,"targetDuration":144,"studyType":62,"phases":4,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":156,"locationsCount":157},"100338853","design-of-an-integrative-algorithm-for-staging-tuberculosis-100338853","NCT03691883","Design of an Integrative Algorithm for Staging Tuberculosis","Design of an Integrative Algorithm for Staging Tuberculosis to Improve Clinical Management.","STAGE-TB","Inclusion Criteria:\n\n* TB diagnosis (all forms), microbiologically confirmed (by AFB+, GenXpert+ or Culture+)\n* Clinical management of the patients being done at Servicios Clínicos, Hospital Universitari Vall d'Hebron-Drassanes or Hospital Universitari Germans Trias i Pujol.\n\nExclusion Criteria:\n\n* Not consenting to data\u002Fsamples donation",{"count":143,"type":23},200,"2 Years","Tuberculosis is a chronic infectious disease that affects 10 million people, 300 in the city of Barcelona, every year. With serious consequences at public health level, it is associated with other diseases, and generated and influenced by many social and psychological factors. This study aims to stage tuberculosis disease by an integrative approach.",[147],"Tuberculosis",[149],"tuberculosis, infectious diseases","2024-12-22",{"date":152,"type":42},"2024-12-27",{"date":154,"type":42},"2018-04-19",{"date":76,"type":23},{"name":48,"class":49},5,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":166,"targetDuration":167,"studyType":62,"phases":4,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":184,"locationsCount":50},"100570388","a-systemic-screening-for-tb-disease-in-high-risk-groups-in-barcelona-100570388","NCT06706596","A Systemic Screening for TB Disease in High-risk Groups in Barcelona","Implementing a Systemic Screening for TB Disease in High-risk Groups in Barcelona Area","SYS-TB-S","Inclusion Criteria:\n\n-Belonging to a population at high risk for tuberculosis (TB)\n\nExclusion Criteria:\n\n-Not belonging to a population at high risk for tuberculosis (TB)",{"count":60,"type":23},"1 Year","The purpose of this screening study is to identify and screen vulnerable population in Barcelona for active pulmonary tuberculosis",[147,170],"Tuberculosis, Pulmonary",[147,172,173,174,175,176,177],"Tuberculosis infection","Tuberculosis screening","Vulnerable populations","Refugees","Migrants","Pulmonary tuberculosis","2024-11-26",{"date":180,"type":42},"2024-11-29",{"date":182,"type":42},"2022-07-22",{"date":76,"type":23},{"name":48,"class":49},""]